Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023
Authors' conclusion
Despite the generally poor prognosis, aggressive treatment, particularly neoadjuvant therapy, has been shown to improve survival. Personalized treatment is crucial for optimizing treatment strategies for PDTC/ATC.
Study context
- Population
- Patients with locally advanced or metastatic poorly differentiated thyroid cancer (PDTC)/anaplastic thyroid cancer (ATC) at Fudan University Shanghai Cancer Center, 2019–2023, in clinical trials or treated per guidelines and expert consensus82 had gene testing
- Participants
- 95 patients
- Exposure
- PDTC vs ATC; neoadjuvant therapy + surgery vs systemic treatment vs supportive care only
- PDTCn = 34
- ATCn = 61
- Outcome
- Median OS
Methodological detailssingle-center
- Single-center
Main finding
As reported in the abstract
P = 0.478
Observational data: associations, not effects.
Further findings
Most frequent gene alterations (82 tested)
BRAF
TERT promoter
TP53
| Outcome | HR (95% CI) | P value |
|---|---|---|
| 1-year OS by treatment (PDTC/ATC)Between Neoadjuvant therapy + surgery and Systemic treatment · across the three treatments | P < 0.001 | |
| OS, adjusted for covariates: neoadjuvant therapy + surgery | 0.216 (0.647–0.718) | P = 0.012 |
- 1-year overall survival (OS) by treatment (PDTC/ATC): Neoadjuvant therapy + surgery 83.3 %
- 1-year OS by treatment (PDTC/ATC): Systemic treatment 51.2 %
- 1-year OS by treatment (PDTC/ATC): Supportive care only 5.7 %
- OS, adjusted for covariates: neoadjuvant therapy + surgery: independent predictor of superior OS; estimate outside printed CI
Treatment received
- PDTC vs ATC: more likely best supportive care, less likely clinical trial enrolment or PD-1 inhibitors
Original publication
Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019–2023. Eur Thyroid J. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →